

Feature

Launch of CORECTIM® Ointment: A New Option for Treating Atopic Dermatitis

The First Topical Medication for Atopic Dermatitis Introduced in About 20 Years

Torii began sales of CORECTIM® Ointment 0.5% on June 24, 2020 for which JT had received manufacturing and marketing approval for an indication of atopic dermatitis in Japan on January 23, 2020.

CORECTIM® Ointment is the world's first topical Janus kinase (JAK) inhibitor for treatment of atopic dermatitis* by inhibiting the action of JAKs, which play key roles in immune activation signaling in cells, thus suppressing the overactivation of immune responses.

*Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritants or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).



Website for patients



- ◆ JT received manufacturing and marketing approval for CORECTIM® Ointment 0.25% for an indication of pediatric atopic dermatitis in Japan. In addition, JT received approval for additional pediatric dosage and administration for CORECTIM® Ointment 0.5% (March 2021).
- ◆ The Phase III clinical study for infant patients (aged under 24 months) is being conducted in Japan (as of April 2021).



Voice of the Customer Support Department



Numerous inquiries to the Customer Support Department

Ever since the approval granted for CORECTIM® Ointment in January 2020, Torii's Customer Support Department has been receiving numerous inquiries, mostly from medical professionals but also from some patients.

Patients' inquiries before the launch of CORECTIM® Ointment included questions about the schedule of the drug's launch and many patients expressed the desire for an early launch. Following the launch, the Customer Support Department received many inquiries about which institution would prescribe CORECTIM® Ointment. Patients' inquiries also included ones concerning safety, such as side effects, and others concerning dosage and administration and how to use the drug.

Among those making inquiries were atopic dermatitis patients who have been receiving treatment for several decades, family members of atopic dermatitis patients who have received many types of treatment since childhood, and people knowledgeable about drugs and treatment methods for atopic dermatitis including CORECTIM® Ointment. These inquiries were indicative of the high expectations of this drug with its novel mechanism of action.

We are making a company-wide effort to help as many patients as possible through the provision of information to medical professionals and patients.